Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis

Abstract Background Determining the relative cost-effectiveness between advanced therapeutic options for ulcerative colitis (UC) may optimize resource utilization. We evaluated total cost per response, cost per remission, and cost of safety events for patients with moderately-to-severely active UC a...

Full description

Bibliographic Details
Main Authors: Vipul Jairath, Russell D. Cohen, Edward V. Loftus, Ninfa Candela, Karen Lasch, Bob G. Schultz
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Gastroenterology
Subjects:
Biological products
Cost-effectiveness
Drug safety
Remission
Ulcerative colitis
Online Access:https://doi.org/10.1186/s12876-022-02590-6

Internet

https://doi.org/10.1186/s12876-022-02590-6

Similar Items